Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, MD, Yun Su, MD MPH, Elias J. Jabbour, MD, Helen Bhattacharyya, PhD, Eric Yan, PhD, Mark Shapiro, MD PhD, Joseph C. Cappelleri, PhD MPH, MS, David I. Marks, MD PhD

Blood (2016) 128 (22): 1599.

https://doi.org/10.1182/blood.V128.22.1599.1599

Published: 2016

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Erica D Warlick, MD, Brian McClune, DO, Tanya L. Pedersen, MPH, Kwang W Awn, PhD, Joseph H. Antin, MD, Jean-Yves Cahn, MD, Marcos DeLima, MD, Vikas Gupta, MD, FRCP, FRCPath, David I Marks, MD, Donald Bunjes, MD, John F. DiPersio, MD, PhD, Steven Devine, Daniel J. Weisdorf, MD

Blood (2011) 118 (21): 494.

https://doi.org/10.1182/blood.V118.21.494.494

Published: 2011

Journal Articles

Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.

David I. Marks, MD, PhD, Tao Wang, PhD, Waleska S. Peréz, MPH, Donald W. Bunjes, MD, PhD, John F. DiPersio, MD, PhD, Martin S. Tallman, MD, Daniel J. Weisdorf, MD

Blood (2009) 114 (22): 872.

https://doi.org/10.1182/blood.V114.22.872.872

Published: 2009

Journal Articles

T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies

B. R Patel, Keiren Kirkland, R. Pearce, Richard E Clark, Charles F. Craddock, BM, MRCP, MRCPath, Effie Liakopolou, Adele K Fielding, PhD, Stephen Mackinnon, MD, Eduardo Olavarria, MD, Michael N Potter, Nigel H. Russell, MD, Bronwen E. Shaw, Anthony H. Goldstone, FRCP, FRCPath, David I Marks, MD

Blood (2008) 112 (11): 4413.

https://doi.org/10.1182/blood.V112.11.4413.4413

Published: 2008

Journal Articles

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Jacob M. Rowe, MD, Georgina Buck, Anthony V Moorman, MD, Martin S Tallman, MD, Susan M Richards, Ph.D, Adele K Fielding, MD, Ph.D, Alan K. Burnett, MD, FRCP, Ian M Franklin, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David I Marks, MD, Selina Luger, MD, Gordon W. Dewald, PhD, PhD, FACMG, Anthony H. Goldstone, FRCP, FRCPath

Blood (2008) 112 (11): 3314.

https://doi.org/10.1182/blood.V112.11.3314.3314

Published: 2008

Journal Articles

Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR

Jeffrey R. Schriber, MD, Manza- A Agovi, MPH, Karen K Ballen, MD, Andrea Bacigalupo, MD, Gregory A. Hale, MD, Vikas Gupta, MD, MRCP, MRCPath, Hillard M. Lazarus, MD, Mark R. Litzow, MD, David I. Marks, MD, Roger H. Giller, MD, Richard T. Maziarz, MD, Martin Bornhauser, MD, Luis M. Isola, MD, Christopher Bredeson, MD, J. Douglas Rizzo, MD, MS

Blood (2008) 112 (11): 794.

https://doi.org/10.1182/blood.V112.11.794.794

Published: 2008

Journal Articles

Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.

David I. Marks, MD, PhD, Waleska S. Pérez, MPH, Vincent He, MS, Mei-Jie Zhang, PhD, Armand Keating, MD, Martin Tallman, MD, Jorge Sierra, MD, Daniel Weisdorf, MD

Blood (2007) 110 (11): 3055.

https://doi.org/10.1182/blood.V110.11.3055.3055

Published: 2007

Journal Articles

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Ram K. Malladi, MD, Andrew J. Peniket, MD, Timothy James Littlewood, MD, Keiren E. Towlson, MSc SRN, Rachel Pearce, John Yin, MD, Jamie D. Cavanagh, MD, Charles Craddock, MD, Kim H. Orchard, MD, David I. Marks, MD

Blood (2006) 108 (11): 3002.

https://doi.org/10.1182/blood.V108.11.3002.3002

Published: 2006

Journal Articles

Utilisation of Stem Cell Transplantation for Lymphoplasmacytic Lymphoma in the UK.

Maria Helena Gilleece, MD, Rachel Pearce, MSc, David C. Linch, FMedSci, Marie Wilson, BSc, Keiren Towlson, MSc, Stephen Mackinnon, MD, Michael Potter, MD, Majid Kamzi, MBChB, John G. Gribben, MD, David I. Marks, MD

Blood (2006) 108 (11): 2980.

https://doi.org/10.1182/blood.V108.11.2980.2980

Published: 2006

Journal Articles

The Role of High Dose Therapy and Stem Cell Rescue in the Management of T-Cell Malignant Lymphomas (TCL): A BSBMT and ABMTRR Study.

Sylvia Feyler, MD, Miles Prince, MD, Rachel Pearce, PhD, Kieren Towlson, Ian Nivison-Smith, David I. Marks, MD, Gordon Cook, MD, PhD

Blood (2005) 106 (11): 678.

https://doi.org/10.1182/blood.V106.11.678.678

Published: 2005

Journal Articles

CMV Specific Immunotherapy: How Many Patients Will Benefit?.

Russell J. Garland, PhD, Paraskevi Diamanti, PhD, Samantha E. West, PhD, Ann Green, MSc, David Carrington, PhD, Sarah J. Groves, BSc, Kerri L. Winship, BSc, Stephen P. Robinson, MD, Anthony Oakhill, MD, Jacqueline M. Cornish, MD, Derwood H. Pamphilon, MD, David I. Marks, MD, Nicholas J. Goulden, MD, Allison G. Blair, PhD, Colin G. Steward, MD

Blood (2004) 104 (11): 2244.

https://doi.org/10.1182/blood.V104.11.2244.2244

Published: 2004

NARROW

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.

T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR

Unrelated Donor (URD) Hematopoietic Stem Cell Transplantation (HCT) for Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Utilisation of Stem Cell Transplantation for Lymphoplasmacytic Lymphoma in the UK.

The Role of High Dose Therapy and Stem Cell Rescue in the Management of T-Cell Malignant Lymphomas (TCL): A BSBMT and ABMTRR Study.

CMV Specific Immunotherapy: How Many Patients Will Benefit?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only